NWPF

News ArchivesRead News

Mouse Model of Parkinson's Disease Shows Improved Brain Function, Motor Skills

Wednesday October 16, 2013

The Sacramento Bee - A paper published in the Journal of Neuroimmune Pharmacology shows that Revalesio's novel therapeutic RNS60 significantly improved biochemical and behavioral (movement) outcomes in a mouse model of Parkinson's disease (PD). The research was conducted by the laboratory of Dr. Kalipada Pahan at Rush University Medical Center.

The model used in the study generates Parkinson's-like symptoms through targeting dopaminergic neurons in the substantia nigra pars compacta, a region of the brain involved in controlling movement. The model produces neuronal death, loss of dopamine, and physical symptoms of the disease. The experiments conducted by Dr. Pahan's group demonstrate that treatment with RNS60 restored dopamine and provided a significant level of protection against neuronal death through upregulation of a protein called I kappa B alpha (IkBa).

"IkBa is an anti-inflammatory protein that helps with survival and function of neurons in neuroinflammatory conditions," said Dr. Pahan. "For therapeutic purpose, the best option would be to increase the level of this protein directly in the brain using a non-toxic medication. Remarkably, RNS60 treatment achieved this goal and thereby protected dopaminergic neurons in the mouse model of PD," Dr. Pahan said.

In addition to protecting the brain from the biochemical damage associated with PD, RNS60 also preserved the motor function of the animals, which the researchers assessed using numerous techniques. The ability to protect dopaminergic neurons, preserve striatal neurotransmitter function, and halt the progression of neurodegeneration and associated symptoms strongly suggest RNS60 as a promising therapeutic for PD and other neuroinflammatory diseases.

Revalesio's director of neurology research, Dr. Supurna Ghosh said, "In this study, RNS60's effect on the central anti-inflammatory mechanism in the glial cells of the brain is remarkable. Based on this work, and research previously published, we are hopeful RNS60 can have significant therapeutic effects in multiple neuroinflammatory and neuro-degenerative diseases. We are moving forward with additional research and human trials to further understand the therapeutic potential of RNS60."

A copy of the paper, Protection of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease by a Physically-Modified Saline Containing Charge-Stabilized Nanobubbles, can be found online at the Journal of Neuroimmune Pharmacology. (http://link.springer.com/article/10.1007/s11481-013-9503-3)

About RNS60: Revalesio is developing the use of RNS60 as a therapeutic that alters whole cell conductance through effects voltage-sensing membrane-bound proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

(16 Oct. 2013). The Sacramento Bee. Mouse Model of Parkinson's Disease Shows Improved Brain Function, Motor Skills Due to Revalesio's RNS60. www.sacbee.com.

Recent News

Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression
Apr 5 - Speech therapy program helps Parkinson’s patients regain speaking ability
Apr 4 - New research maps out pesticide exposure and Parkinson's disease in Nebraska
Apr 4 - The rogue immune cells that wreck the brain
Mar 28 - Chemists identify structure of protein that forms fibrils in Parkinson's patients
Mar 25 - UPDATE 1-FDA staff says Acadia's drug for Parkinson's disease psychosis is effective
Mar 23 - The virus that could cure Alzheimer's, Parkinson's and more
Mar 21 - Antipsychotic drugs may do significantly more harm to Parkinson's disease patients
Mar 21 - Rosacea Might Boost Parkinson's Risk: Study
Mar 21 - Apple CareKit Could Completely Change What It's Like To Live With Parkinson's Disease & Epilepsy
Mar 17 - Coach Improves Health and Turns Around Texas A&M
Mar 11 - Lifestyle: What I Learned Training for 'American Ninja Warrior'
Mar 4 - Lifestyle: The art and heartbreak of caregiving